Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 12/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.54 |
| ▸ | USP2 | O75604 | 12/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22804781 | 0.84 | CYP3A4 (0.51) | CYP2C19ALDH1A1MAPK1CYP3A4USP2 | |
| SCHEMBL22804382 | 0.81 | CYP3A4 (0.52) | CYP2C19ALDH1A1MAPK1CYP3A4USP2 | |
| SCHEMBL5015647 | 0.80 | AKR1C3 (0.65) | CYP2C19ALDH1A1USP2SMN1; SMN2TSHR | |
| SCHEMBL22805048 | 0.79 | CYP3A4 (0.55) | CYP2C19ALDH1A1MAPK1CYP3A4USP2 | |
| SCHEMBL23439910 | 0.78 | CYP3A4 (0.67) | CYP2C19ALDH1A1MAPK1CYP3A4USP2 | |
| SCHEMBL22396274 | 0.77 | USP2 (0.62) | CYP2C19ALDH1A1MAPK1CYP3A4USP2 | |
| SCHEMBL23551895 | 0.76 | CYP3A4 (0.52) | CYP2C19ALDH1A1MAPK1CYP3A4USP2 | |
| SCHEMBL23199735 | 0.76 | AKR1C3 (0.42) | CYP2C19ALDH1A1MAPK1CYP3A4USP2 | |
| SCHEMBL31237127 | 0.76 | TSHR (0.44) | CYP2C19ALDH1A1MAPK1CYP3A4USP2 | |
| SCHEMBL23123044 | 0.76 | ALDH1A1 (0.48) | CYP2C19ALDH1A1MAPK1CYP3A4USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024201308-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | 주식회사 엘지화학 | 2024-10-03 | — | — | WO | disclosed |
| US-20240076300-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | US | disclosed |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| EP-3986896-B1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2023-03-15 | — | — | EP | disclosed |
| US-20230054473-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-3986896-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| WO-2021127561-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020254572-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | CYP2C19 3078/4885ALDH1A1 2283/4885MAPK1 1409/4885 |
| US-20230054473-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | CYP2C19 1096/4885ALDH1A1 3894/4885MAPK1 619/4885 |
| US-20240076300-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | CYP2C19 3078/4885ALDH1A1 2283/4885MAPK1 1409/4885 |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | CYP2C19 3078/4885ALDH1A1 2283/4885MAPK1 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.